Laurus Labs Share Price

    NSE
    776.8
    +18.25 (2.35%)
    LAURUSLABS • 04 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    66.92%

    3Y Annualised Return

    17.89%

    5Y Annualised Return

    47.35%

    The current prices are delayed, login or Open Demat Account for live prices.

    Laurus Labs Stock Performance

    1W Return10.57
    1Y Return70.76
    Today's Low756.65
    Prev. Close758.55
    Mkt Cap (Cr.)41,845.99
    1M Return24.49
    3Y Return65.23
    52-Week High777.9
    Open759.80
    PE Ratio122.98
    6M Return26.85
    Today's High777.9
    52-Week Low414
    Face Value2

    Laurus Labs Company background

    Founded in: 2005

    Laurus Labs is a science-driven, fully integrated pharmaceutical and biotechnology company headquartered in India. The company has established itself as a leader in the generic Active Pharmaceutical Ingredients (APIs) market, particularly in the therapeutic areas of antiretrovirals (ARVs), Hepatitis C, and Oncology. Laurus Labs also manufactures APIs for other therapeutic areas, including asthma, ophthalmology, antidiabetics, cardiovascular diseases, and proton pump inhibitors (PPIs). With a strong focus on research and development (R&D), the company has positioned itself as a leading player in the global pharmaceutical market, providing high-quality, affordable medicines to patients across the world. Its emphasis on innovation, manufacturing capabilities, and strategic investments has helped Laurus Labs grow its market share and deliver significant value to its stakeholders.

    Laurus Labs was founded in 2005 under the name Laurus Labs Private Limited in Hyderabad, Andhra Pradesh. In 2007, the company transitioned into a public limited company and changed its name to Laurus Labs Limited. A significant transformation occurred in 2007 when Laurus Labs entered into a strategic partnership with Aptuit Singapore, which led to a brief change in the company’s name to Aptuit Laurus Limited. However, this partnership dissolved in 2012, and the company reverted to its original name, Laurus Labs Private Limited. The company finally became Laurus Labs Limited once again in 2016.

    The company’s early success was driven by its investments in R&D and manufacturing capabilities. Laurus Labs quickly grew to become one of the leading suppliers of ARV APIs, focusing on the high-demand markets of Sub-Saharan Africa, Southeast Asia, and Latin America. These regions, often reliant on donor-funded access to medicines, provided a strong growth opportunity for Laurus Labs, particularly in the ARV sector. Over time, Laurus expanded its product portfolio, which now includes APIs for oncology, antidiabetic drugs, and other therapeutic categories. This expansion allowed the company to diversify its business and enter new markets.

    Laurus Labs operates four state-of-the-art manufacturing facilities located in Visakhapatnam, Andhra Pradesh. Three of these facilities focus on the production of APIs, while the fourth facility is dedicated to the manufacturing of Finished Dosage Formulations (FDFs). The company’s manufacturing plants are equipped with cutting-edge technology and comply with international standards, ensuring high-quality production of APIs and finished formulations. These facilities are crucial in meeting the increasing demand for affordable medicines in both developed and emerging markets.

    The company’s investment in infrastructure has been a key factor in its growth. In addition to expanding its manufacturing capabilities, Laurus Labs has strategically invested in research and development (R&D) to develop and commercialize new products. The company’s R&D center in Hyderabad is dedicated to the development of generic APIs and formulations, enabling it to stay ahead of competitors in terms of product innovation and quality.

    Laurus Labs operates through four primary business segments: Generics APIs, Generics FDFs, Synthesis, and Ingredients. Each segment plays a vital role in the company’s overall growth and market presence.

    Generics APIs: This segment is the backbone of Laurus Labs, involving the development, manufacture, and sale of APIs and advanced intermediates. The company has become a leading supplier of ARV APIs, which are crucial in the treatment of HIV/AIDS. Laurus also manufactures APIs for oncology and other therapeutic areas such as asthma, diabetes, and cardiovascular diseases. Its strong capabilities in API development and manufacturing have made it a preferred supplier for major multinational pharmaceutical companies.

    Generics FDFs: Laurus Labs has made significant strides in the Generics Finished Dosage Forms (FDFs) business. This segment involves the development and production of oral solid formulations. The company’s investments in FDF manufacturing have allowed it to diversify its product portfolio and expand its market presence in the generics sector.

    Synthesis: The Synthesis segment includes contract development and manufacturing services (CDMO) for global pharmaceutical companies. Laurus Labs provides custom synthesis of intermediates and APIs, supporting its clients in bringing innovative therapies to market. This segment has contributed to the company’s global reach and allowed it to collaborate with leading pharmaceutical companies worldwide.

    Ingredients: The company manufactures specialty ingredients for use in the nutraceutical and cosmeceutical sectors. This segment has gained momentum over the years, with Laurus Labs focusing on the growing demand for ingredients used in dietary supplements and cosmetic formulations. This diversification into the nutraceutical and cosmeceutical industries has opened new revenue streams for Laurus Labs.

    The company has launched 59 products since its inception, with a particular emphasis on ARVs and oncology drugs. Its products are sold globally, and Laurus Labs has forged strong relationships with key customers such as Aspen Pharmacare, Aurobindo Pharma, Cipla, Mylan Laboratories, NATCO Pharma, and Strides Shasun. The company’s focus on delivering high-quality, cost-effective products has made it a trusted supplier in both emerging and developed markets.

    Laurus Labs has made several strategic acquisitions and entered into key partnerships to strengthen its market position. One of the most notable acquisitions was in 2016 when the company acquired a 100% stake in Sriam Labs Private Limited, a company engaged in the design, development, and manufacture of active pharmaceutical intermediates. This acquisition allowed Laurus Labs to expand its capabilities in the API sector and realize synergies between the two businesses.

    The company also acquired a 72.55% stake in Richcore Lifesciences, a biotechnology company focused on the production of specialty enzymes and fermentation-based products. This acquisition aligns with Laurus Labs' strategy to expand its capabilities in the biopharmaceutical sector and diversify its product offerings. Additionally, Laurus Labs has formed strategic partnerships with global players such as Dr. Reddy’s Laboratories, Natco Pharma, and the Global Fund. These partnerships have enabled Laurus Labs to expand its market presence and increase its share of the global API market. The company’s successful partnerships with multinational companies have helped it penetrate new markets, particularly in Europe and the United States.

    Laurus Labs has experienced strong financial growth since its inception. The company’s revenues have increased steadily, driven by its expanding product portfolio and strong market demand. Its business is well-diversified, with substantial revenue coming from generics APIs, FDFs, synthesis, and ingredients. The company’s ability to expand its market presence, launch new products, and form strategic partnerships has helped it maintain a strong financial position.

    Looking ahead, Laurus Labs is focused on expanding its capabilities and market reach. The company plans to continue investing in its R&D and manufacturing infrastructure to support the development of new products and maintain its competitive edge. Laurus Labs is also increasingly focused on growing its integrated generics finished dosage forms (FDFs) business, which has shown promising growth in recent years.

    The company’s share price has been influenced by its strong performance, global expansion, and strategic investments. Investors have shown confidence in Laurus Labs due to its consistent revenue growth, strong customer relationships, and innovative product portfolio. As the company continues to expand its global presence and introduce new products, the Laurus Labs share price is expected to remain a key indicator of its success in the pharmaceutical market.

    Laurus Labs has successfully established itself as a leader in the pharmaceutical and biotechnology sectors, with a strong focus on generics APIs, FDFs, synthesis, and ingredients. The company’s strategic investments in R&D, manufacturing infrastructure, and acquisitions have enabled it to expand its market share and diversify its product offerings. As Laurus Labs continues to innovate and expand its global presence, it remains well-positioned for future growth. Investors looking at Laurus Labs Share Price can expect the company to continue making significant strides in the pharmaceutical industry while delivering value to its stakeholders. With its ongoing commitment to research, development, and strategic partnerships, Laurus Labs is poised to remain a key player in the global pharmaceutical market.

    As of 04 Jul, 2025, Laurus Labs share price is ₹776. The stock opened at ₹759.8 and had closed at ₹758.6 the previous day. During today’s trading session, Laurus Labs share price moved between ₹756.65 and ₹777.90, with an average price for the day of ₹767.27. Over the last 52 weeks, the stock has recorded a low of ₹414.00 and a high of ₹777.90. In terms of performance, Laurus Labs share price has increased by 26.8% over the past six months and has increased by 66.92% over the last year.

    Read More
    Laurus Labs SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹92,60,889 (+42.48%)

    Daily SIP of 25,000 would have become 92,60,889 in 1 year with a gain of 27,60,889 (+42.48%)

    View details of Market Depth

    Laurus Labs Fundamental

    Market Cap (in crs)

    41,845.99

    Face Value

    2

    Turnover (in lacs)

    25,066.45

    Key Metrics

    Qtr Change %
    New 52W High today
    35.1
    Dividend yield 1yr %
    Low in industry
    0.2

    Laurus Labs Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Laurus Labs Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    1720.3 Cr
    1415.05 Cr
    1223.7 Cr
    1194.91 Cr
    1439.67 Cr
    Laurus Labs Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    5613.89 Cr
    5067.17 Cr
    6046.55 Cr
    4949.15 Cr
    4837.17 Cr
    2837.65 Cr
    Laurus Labs Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    233.87 Cr
    90.61 Cr
    17.72 Cr
    12.21 Cr
    75.32 Cr
    Laurus Labs Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    354.41 Cr
    168.21 Cr
    796.64 Cr
    832.43 Cr
    983.82 Cr
    255.27 Cr

    Laurus Labs Result Highlights

    • Laurus Labs Ltd reported a 2.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.5%.

    • Its expenses for the quarter were up by 4.4% QoQ and 9.3% YoY.

    • The net profit decreased 19.3% QoQ and decreased 28.7% YoY.

    • The earnings per share (EPS) of Laurus Labs Ltd stood at 1.4 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Laurus Labs

    Promoter
    27.6%
    Foreign Institutions
    25.5%
    Mutual Funds
    6.9%
    Domestic Institutions
    11.8%
    Public
    35.1%
    Promoter
    27.6%
    Foreign Institutions
    25.6%
    Mutual Funds
    7.6%
    Domestic Institutions
    12.7%
    Public
    34.1%
    Promoter
    27.2%
    Foreign Institutions
    26.1%
    Mutual Funds
    8.2%
    Domestic Institutions
    13%
    Public
    33.7%
    Promoter
    27.2%
    Foreign Institutions
    25.7%
    Mutual Funds
    9.2%
    Domestic Institutions
    13.5%
    Public
    33.6%
    Promoter
    27.2%
    Foreign Institutions
    26%
    Mutual Funds
    6.7%
    Domestic Institutions
    11.8%
    Public
    35.1%
    Promoter
    27.2%
    Foreign Institutions
    25.4%
    Mutual Funds
    5.6%
    Domestic Institutions
    11.1%
    Public
    36.3%

    Laurus Labs Technical Analysis

    Moving Averages Analysis
    776.8
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    750.40
    10Day EMA
    725.60
    12Day EMA
    718.20
    20Day EMA
    696.30
    26Day EMA
    684.70
    50Day EMA
    656.20
    100Day EMA
    624.30
    200Day EMA
    580.40
    5Day SMA
    752.40
    10Day SMA
    715.00
    20Day SMA
    689.80
    30Day SMA
    665.50
    50Day SMA
    641.20
    100Day SMA
    615.20
    150Day SMA
    603.40
    200Day SMA
    572.50
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    1370499 Rs
    3319026 Rs
    Week Rs
    1809680 Rs
    4010889 Rs
    Month Rs
    1158929 Rs
    2526038 Rs
    770.18
    Pivot
    Resistance
    First Resistance
    783.72
    Second Resistance
    791.43
    Third Resistance
    804.97
    Support
    First Support
    762.47
    Second support
    748.93
    Third Support
    741.22
    Relative Strength Index
    82.91
    Money Flow Index
    81.84
    MACD
    33.53
    MACD Signal
    23.95
    Average True Range
    18.80
    Average Directional Index
    40.15
    Rate of Change (21)
    21.13
    Rate of Change (125)
    26.57
    Name
    Holding Percent
    SBI ARBITRAGE OPPORTUNITIES FUND
    1.82
    DSP ARBITRAGE FUND
    1.16
    NEW WORLD FUND INC
    6.5
    SMALLCAP WORLD FUND, INC
    4.25
    GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY P
    1.18
    KOTAK FUNDS - INDIA MIDCAP FUND
    1.16
    VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND
    1.02
    LIFE INSURANCE CORPORATION OF INDIA
    2.7

    Laurus Labs Latest News

    01 JUL 2025 | Tuesday

    Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Credit Rating

    30 JUN 2025 | Monday

    Laurus Labs nears record high after 4 years, zooms 84% from 52-week low

    27 JUN 2025 | Friday

    Laurus Labs Ltd - 540222 - Closure of Trading Window

    View More

    Laurus Labs Share Price FAQs

    Laurus Labs share price is ₹776.8 in NSE and ₹776.25 in BSE as on 4/7/2025.

    Laurus Labs share price in the past 1-year return was 70.75. The Laurus Labs share hit a 1-year low of Rs. 414 and a 1-year high of Rs. 777.9.

    The market cap of Laurus Labs is Rs. 41845.99 Cr. as of 4/7/2025.

    The PE ratios of Laurus Labs is 122.98 as of 4/7/2025.

    The PB ratios of Laurus Labs is 9.16 as of 4/7/2025

    The Mutual Fund Shareholding in Laurus Labs was 6.88% at the end of 4/7/2025.

    You can easily buy Laurus Labs shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Laurus Labs share price is ₹777.9 and ₹414 as of 4/7/2025.

    Please be aware that Laurus Labs stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.53
    +0.26 (+0.40%)
    139.24
    -0.46 (-0.33%)
    689.05
    -1.35 (-0.20%)
    2,599.10
    -12.10 (-0.46%)
    166.67
    -0.85 (-0.51%)
    391.40
    +0.75 (+0.19%)
    163.01
    -2.90 (-1.75%)
    261.40
    +0.55 (+0.21%)
    427.55
    +1.30 (+0.30%)
    401.00
    +1.10 (+0.28%)
    Top Gainers
    925.30
    +15.15 (+1.66%)
    1,640.70
    +22.00 (+1.36%)
    1,307.40
    +16.10 (+1.25%)
    1,442.80
    +16.90 (+1.19%)
    270.05
    +3.00 (+1.12%)
    Top Losers
    5,456.00
    -735.00 (-11.87%)
    163.01
    -2.90 (-1.75%)
    5,629.00
    -87.00 (-1.52%)
    1,655.20
    -16.70 (-1.00%)
    12,646.00
    -106.00 (-0.83%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -